Fibroblast growth factor 2 alters the oxytocin receptor in a developmental model of anxiety-like behavior in male rat pups.
We aimed to determine the short-term effects of early-life stress in the form of maternal separation (MS) on anxiety-like behavior in male rat pups. In order to assess anxiety, we measured 40kHz separation-induced ultrasonic vocalizations (USV) on postnatal day (PND) 11. We further aimed to evaluate the potential involvement of two neurochemical systems known to regulate social and anxiety-like behaviors throughout life: oxytocin (OT) and fibroblast growth factor 2 (FGF2). For these purposes, we tested the effects of neonatal administration (on PND1) of an acute dose of FGF2 on USV and its potential interaction with MS. In addition, we validated the anxiolytic effects of OT and measured oxytocin receptor (OTR) gene expression, binding and epigenetic regulation via histone acetylation. Our results show that MS potentiated USV while acute administration of OT and FGF2 attenuated them. Further, we found that both FGF2 and MS increased OTR gene expression and the association of acH3K14 with the OTR promoter in the bed nucleus of the stria terminalis (BNST). Comparable changes, though not as pronounced, were also found for the central amygdala (CeA). Our findings suggest that FGF2 may exert its anxiolytic effects in male MS rats by a compensatory increase in the acetylation of the OTR promoter to overcome reduced OT levels in the BNST.
Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065, United States.
Yoav
Y
Litvin
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, United States.
Cortney A
CA
Turner
Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065, United States.
Mariel B
MB
Rios
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, United States.
Pamela M
PM
Maras
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, United States.
Sraboni
S
Chaudhury
Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065, United States.
Miriam R
MR
Baker
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, United States.
Peter
P
Blandino
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, United States.
Stanley J
SJ
Watson
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, United States.
Huda
H
Akil
Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065, United States. Electronic address: mcewen@rockefeller.edu.
Bruce
B
McEwen
D000818:Animals; D000831:Animals, Newborn; D001007:Anxiety / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects*; D066274:Central Amygdaloid Nucleus / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D044127:Epigenesis, Genetic / Q000187:drug effects; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D048788:Growth and Development / Q000187:drug effects* / Q000235:genetics; D008297:Male; D008426:Maternal Deprivation; D010121:Oxytocin / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018045:Receptors, Oxytocin / Q000235:genetics* / Q000378:metabolism; D012686:Septal Nuclei / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism
D018045:Receptors, Oxytocin; D016222:Fibroblast Growth Factor 2; D010121:Oxytocin
Anxiety; Depression; FGF2; Fear; Oxytocin; Stress
Rev Neurosci. 2000;11(4):383-408
11065281
Neuroscience. 2010 Aug 25;169(2):665-73
20580660
Brain Res. 1995 Dec 1;701(1-2):201-26
8925285
Horm Behav. 2014 Apr;65(4):427-33
24681215
Behav Brain Res. 2007 Jan 10;176(1):170-86
17000015
Horm Behav. 2006 Nov;50(4):506-17
16890230
Nature. 2013 Apr 11;496(7444):224-8
23515155
Prog Brain Res. 2002;139:147-62
12436933
Psychoneuroendocrinology. 2013 Sep;38(9):1883-94
23856187
Prog Brain Res. 2008;170:337-50
18655894
J Neurosci. 2004 Sep 1;24(35):7762-70
15342744
Neuron. 2012 Oct 4;76(1):160-74
23040813
Nat Neurosci. 2013 Jul;16(7):919-24
23727821
Neuroscience. 1998 Jun;84(4):967-96
9578390
Neuropsychopharmacology. 2011 Oct;36(11):2159-68
21677650
Proc Natl Acad Sci U S A. 2011 May 10;108(19):8021-5
21518861
Dev Psychopathol. 2001 Summer;13(3):419-49
11523842
Neuropsychopharmacology. 2000 Mar;22(3):219-29
10693149
Neuropeptides. 2010 Oct;44(5):391-8
20591479
Front Neuroendocrinol. 2014 Apr;35(2):234-44
24456850
Science. 2005 Apr 8;308(5719):245-8
15821089
J Neurosci. 2009 May 13;29(19):6379-87
19439615
Neuropharmacology. 2010 Jan;58(1):78-87
19560475
Curr Protoc Neurosci. 2002 Feb;Chapter 8:Unit 8.14
18428567
Psychopharmacology (Berl). 1999 Feb;142(1):95-101
10102788
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11834-9
25071177
Brain Res Bull. 2000 Oct;53(3):283-9
11113582
Psychopharmacol Bull. 1993;29(3):409-14
8121969
Hippocampus. 2012 Jan;22(1):82-91
20848608
J Neurosci. 1999 Jul 15;19(14):6006-16
10407038
Novartis Found Symp. 2005;268:190-8; discussion 198-200, 242-53
16206881
Neuropsychopharmacology. 2010 Jan;35(1):105-35
19693004
Behav Brain Res. 2014 Mar 15;261:315-22
24406721
Neuropsychopharmacology. 2007 May;32(5):977-88
17035935
Biol Psychiatry. 2012 Aug 15;72(4):254-5
22840947
Eur J Pharmacol. 1991 Oct 2;203(1):149-52
1665788